Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Viatris to Participate in Upcoming Investor Conferences

2025-11-24
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in December 2025.

Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know

2025-11-21
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

2025-11-20
Sol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug’s commercial potentialIn September 2025, Sol-Gel announced Health Canada approval of EPSOLAYSol-Gel signed an additional agreement with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO NESS ZIONA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering t

Collaborating to Address Antimicrobial Resistance

2025-11-18
NORTHAMPTON, MA / ACCESS Newswire / November 18, 2025 / Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials and in partnership with others, including ...

Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18

Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q3 2025 Update

2025-11-16
Discover Davis Selected Advisers' Q3 2025 portfolio changes, top holdings, and new investments.

Viatris Inc. stock falls Friday, underperforms market

2025-11-14
Viatris Inc. stock falls Friday, underperforms market

Viatris (VTRS): Assessing Valuation After Raised 2025 Guidance and Strong Earnings Signals

2025-11-14
Viatris (VTRS) grabbed the spotlight after posting third quarter revenues that came in ahead of expectations and raising its guidance for both full-year revenue and adjusted EBITDA. See our latest analysis for Viatris. Momentum has picked up for Viatris in recent weeks, especially after management doubled down on growth ambitions and raised guidance. These moves sparked a 9.9% jump in the share price over the past month alone. Despite year-to-date and one-year total shareholder returns still...

How Recent Developments Are Rewriting the Story for Viatris

2025-11-13
Viatris has seen its Fair Value Estimate nudge higher from $12.00 to $12.13 as analysts revise their assumptions for the company's future growth and market opportunities. This modest upward adjustment reflects improved revenue expectations and reduced business risk, along with growing optimism about Viatris's ability to execute on its initiatives. Stay tuned to discover how ongoing shifts in analyst sentiment may impact your understanding of Viatris’s evolving narrative in the months...

Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025

2025-11-13
Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025. The list of 25 global leaders was selected from organizations that participated in Great Place To Work's employee survey process, with over 9 million responses representing more than 25 million employees worldwide. To be considered for the list, companies must have 5,000 or more global employees, be identified as outstanding global employers with recognition on at least